Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Cutaneous Pseudolymphoma Medication

  • Author: Christine J Ko, MD; Chief Editor: William D James, MD  more...
 
Updated: May 17, 2016
 

Medication Summary

The goals of pharmacotherapy for cutaneous pseudolymphoma are to reduce morbidity and to prevent complications.

Next

Corticosteroids

Class Summary

These agents have anti-inflammatory properties and cause profound and varied metabolic effects. In addition, these agents modify the body’s immune response to diverse stimuli.

Hydrocortisone valerate 0.2% (Ala Cort, HydroSKIN, Locoid, Pandel, NuZon, Dermasorb, NuCort, Rederm, Westcort)

 

Hydrocortisone valerate is an adrenocorticosteroid derivative suitable for application to skin or external mucous membranes. It has mineralocorticoid and glucocorticoid effects, resulting in anti-inflammatory activity. It is used to treat inflammatory dermatosis responsive to steroids. Hydrocortisone valerate decreases inflammation by suppressing the migration of polymorphonuclear leukocytes and reversing capillary permeability.

Betamethasone (Diprolene, Luxiq, Alphatrex)

 

Betamethasone is for inflammatory dermatosis responsive to steroids. It decreases inflammation by suppressing the migration of polymorphonuclear leukocytes and reversing capillary permeability.

Clobetasol (Temovate, Clobex, Clux)

 

Clobetasol is a class I superpotent topical steroid; it suppresses mitosis and increases the synthesis of proteins that decrease inflammation and cause vasoconstriction.

Fluocinonide (Vanos)

 

Fluocinonide is a high-potency topical corticosteroid that inhibits cell proliferation; it is immunosuppressive and anti-inflammatory.

Desonide (DesOwen, Verdeso, LoKara)

 

Desonide stimulates the synthesis of enzymes that decrease inflammation. It suppresses mitotic activity and causes vasoconstriction.

Fluocinolone (Capex, Derma-Smoothe/FS, Synalar)

 

Fluocinolone is a fluorinated corticosteroid of moderate potency at the 0.025% concentration and low potency at the 0.01% concentration (class 6). It has anti-inflammatory, antipruritic, and vasoconstrictive properties.

Previous
 
Contributor Information and Disclosures
Author

Christine J Ko, MD Associate Professor, Departments of Dermatology and Pathology, Yale University School of Medicine

Christine J Ko, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, International Society of Dermatopathology

Disclosure: Nothing to disclose.

Coauthor(s)

Earl J Glusac, MD Professor, Departments of Pathology and Dermatology, Yale University School of Medicine

Earl J Glusac, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Jon H Meyerle, MD Assistant Professor, Department Dermatology, Uniformed Services University of the Health Sciences; Assistant Professor, Department of Dermatology, Johns Hopkins University School of Medicine; Chief, Immunodermatology, Walter Reed National Military Medical Center

Jon H Meyerle, MD is a member of the following medical societies: American Academy of Dermatology, Sigma Xi

Disclosure: Nothing to disclose.

Inbal Braunstein, MD Assistant Professor, Department of Dermatology, Johns Hopkins University School of Medicine

Disclosure: Nothing to disclose.

Chief Editor

William D James, MD Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

William D James, MD is a member of the following medical societies: American Academy of Dermatology, Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Acknowledgements

Donald Belsito, MD Professor of Clinical Dermatology, Department of Dermatology, Columbia University Medical Center

Donald Belsito, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Contact Dermatitis Society, Dermatology Foundation, New York County Medical Society, New York Dermatological Society, Noah Worcester Dermatological Society, and Phi Beta Kappa

Disclosure: Nothing to disclose.

Inbal Braunstein University of Pennsylvania School of Medicine

Disclosure: Nothing to disclose.

Günter Burg, MD Professor and Chairman Emeritus, Department of Dermatology, University of Zürich School of Medicine; Delegate of The Foundation for Modern Teaching and Learning in Medicine Faculty of Medicine, University of Zürich, Switzerland

Günter Burg, MD is a member of the following medical societies: American Academy of Dermatology, American Dermatological Association, International Society for Dermatologic Surgery, North American Clinical Dermatologic Society, and Pacific Dermatologic Association

Disclosure: Nothing to disclose.

Dirk M Elston, MD Director, Ackerman Academy of Dermatopathology, New York

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Jacqueline M Junkins-Hopkins, MD Associate Professor, Director, Division of Dermatopathology and Oral Pathology, Department of Dermatology, Johns Hopkins Medical Institutions

Jacqueline M Junkins-Hopkins, MD is a member of the following medical societies: American Academy of Dermatology, American College of Physicians, and American Society of Dermatopathology

Disclosure: Nothing to disclose.

Michael S Lehrer, MD Clinical Assistant Professor, Department of Dermatology, University of Pennsylvania

Michael S Lehrer, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Mohs Micrographic Surgery and Cutaneous Oncology, and American Society for Dermatologic Surgery

Disclosure: Nothing to disclose.

Daniel S Loo, MD Associate Professor of Dermatology, Residency Program Director, Department of Dermatology, Tufts Medical Center

Daniel S Loo, MD is a member of the following medical societies: American Academy of Dermatology and Association of Professors of Dermatology

Disclosure: Nothing to disclose.

Richard P Vinson, MD Assistant Clinical Professor, Department of Dermatology, Texas Tech University School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Association of Military Dermatologists, Texas Dermatological Society, and Texas Medical Association

Disclosure: Nothing to disclose.

References
  1. Brodell RT, Santa Cruz DJ. Cutaneous pseudolymphomas. Dermatol Clin. 1985 Oct. 3(4):719-34. [Medline].

  2. Choi TS, Doh KS, Kim SH, Jang MS, Suh KS, Kim ST. Clinicopathological and genotypic aspects of anticonvulsant-induced pseudolymphoma syndrome. Br J Dermatol. 2003 Apr. 148(4):730-6. [Medline].

  3. Bergman R. Pseudolymphoma and cutaneous lymphoma: facts and controversies. Clin Dermatol. 2010 Sep-Oct. 28(5):568-74. [Medline].

  4. Albrecht J, Fine LA, Piette W. Drug-associated lymphoma and pseudolymphoma: recognition and management. Dermatol Clin. 2007 Apr. 25(2):233-44, vii. [Medline].

  5. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg. 1996 Dec. 15(4):250-7. [Medline].

  6. Callot V, Roujeau JC, Bagot M, Wechsler J, Chosidow O, Souteyrand P, et al. Drug-induced pseudolymphoma and hypersensitivity syndrome. Two different clinical entities. Arch Dermatol. 1996 Nov. 132(11):1315-21. [Medline].

  7. Maubec E, Pinquier L, Viguier M, et al. Vaccination-induced cutaneous pseudolymphoma. J Am Acad Dermatol. 2005 Apr. 52(4):623-9. [Medline].

  8. Magro CM, Crowson AN, Kovatich AJ, Burns F. Drug-induced reversible lymphoid dyscrasia: a clonal lymphomatoid dermatitis of memory and activated T cells. Hum Pathol. 2003 Feb. 34(2):119-29. [Medline].

  9. Ploysangam T, Breneman DL, Mutasim DF. Cutaneous pseudolymphomas. J Am Acad Dermatol. 1998 Jun. 38(6 Pt 1):877-95; quiz 896-7. [Medline].

  10. Magro CM, Crowson AN. Drug-induced immune dysregulation as a cause of atypical cutaneous lymphoid infiltrates: a hypothesis. Hum Pathol. 1996 Feb. 27(2):125-32. [Medline].

  11. Cerroni L, Kerl H. Diagnostic immunohistology: cutaneous lymphomas and pseudolymphomas. Semin Cutan Med Surg. 1999 Mar. 18(1):64-70. [Medline].

  12. Kazandjieva J, Tsankov N. Tattoos: dermatological complications. Clin Dermatol. 2007 Jul-Aug. 25(4):375-82. [Medline].

  13. Porto DA, Comfere NI, Myers LM, Abbott JJ. Pseudolymphomatous reaction to varicella zoster virus vaccination: role of viral in situ hybridization. J Cutan Pathol. 2009 Nov 4. [Medline].

  14. Michaels B, Michaels J, Mobini N. Prominent lymphoid infiltrate with a pseudolymphoma-like morphology: a new histological finding of injectable liquid silicone. J Cutan Pathol. 2009 Nov. 36(11):1224-6. [Medline].

  15. Camilot D, Arnez ZM, Luzar B, Pizem J, Zgavec B, Falconieri G. Cutaneous pseudolymphoma following tattoo application: report of two new cases of a potential lymphoma mimicker. Int J Surg Pathol. 2012 Jun. 20(3):311-5. [Medline].

  16. Altamura D, Calonje E, Liau Jl, Rogers M, Verdolini R. Diffuse cutaneous pseudolymphoma due to therapy with medicinal leeches. JAMA Dermatol. 2014 Jul. 150(7):783-4. [Medline].

  17. Bouloc A, Delfau-Larue MH, Lenormand B, Meunier F, Wechsler J, Thomine E, et al. Polymerase chain reaction analysis of immunoglobulin gene rearrangement in cutaneous lymphoid hyperplasias. French Study Group for Cutaneous Lymphomas. Arch Dermatol. 1999 Feb. 135(2):168-72. [Medline].

  18. Baldassano MF, Bailey EM, Ferry JA, Harris NL, Duncan LM. Cutaneous lymphoid hyperplasia and cutaneous marginal zone lymphoma: comparison of morphologic and immunophenotypic features. Am J Surg Pathol. 1999 Jan. 23(1):88-96. [Medline].

  19. Kitagawa KH, Grassi M. Zoledronic acid-induced cutaneous B-cell pseudolymphoma. J Am Acad Dermatol. 2011 Dec. 65(6):1238-40. [Medline].

  20. Addeo R, Montella L, Baldi A, Cennamo G, Guarrasi R, Faiola V, et al. Atypical cutaneous lymphoid hyperplasia induced by chemotherapy in a patient with advanced colon carcinoma. Clin Colorectal Cancer. 2007 Nov. 6(10):728-30. [Medline].

  21. Welsh JP, Ko C, Hsu WT. Lymphomatoid drug reaction secondary to methylphenidate hydrochloride. Cutis. 2008 Jan. 81(1):61-4. [Medline].

  22. Braun RP, French LE, Feldmann R, Chavaz P, Saurat JH. Cutaneous pseudolymphoma, lymphomatoid contact dermatitis type, as an unusual cause of symmetrical upper eyelid nodules. Br J Dermatol. 2000 Aug. 143(2):411-4. [Medline].

  23. Goyal A, Moore JB, Gimbel D, Carter JB, Kroshinsky D, Ferry JA, et al. PD-1, S-100 and CD1a expression in pseudolymphomatous folliculitis, primary cutaneous marginal zone B-cell lymphoma (MALT lymphoma) and cutaneous lymphoid hyperplasia. J Cutan Pathol. 2015 Jan. 42 (1):6-15. [Medline].

  24. Bachelez H. The clinical use of molecular analysis of clonality in cutaneous lymphocytic infiltrates. Arch Dermatol. 1999 Feb. 135(2):200-2. [Medline].

  25. Burg G, Kerl H, Schmoeckel C. Differentiation between malignant B-cell lymphomas and pseudolymphomas of the skin. J Dermatol Surg Oncol. 1984 Apr. 10(4):271-5. [Medline].

  26. El-Dars LD, Statham BN, Blackford S, Williams N. Lymphocytoma cutis treated with topical tacrolimus. Clin Exp Dermatol. 2005 May. 30(3):305-7. [Medline].

  27. Baumgartner-Nielsen J, Lorentzen H. Imiquimod 5%: a successful treatment for pseudolymphoma. Acta Derm Venereol. 2014 Jul. 94(4):469. [Medline].

  28. Singletary HL, Selim MA, Olsen E. Subcutaneous interferon alfa for the treatment of cutaneous pseudolymphoma. Arch Dermatol. 2012 May. 148(5):572-4. [Medline].

  29. Tomar S, Stoll HL, Grassi MA, Cheney R. Treatment of cutaneous pseudolymphoma with interferon alfa-2b. J Am Acad Dermatol. 2009 Jan. 60(1):172-4. [Medline].

  30. Mikasa K, Watanabe D, Kondo C, Tamada Y, Matsumoto Y. Topical 5-aminolevulinic acid-based photodynamic therapy for the treatment of a patient with cutaneous pseudolymphoma. J Am Acad Dermatol. 2005 Nov. 53(5):911-2. [Medline].

  31. Lucinda TS, Hazel OH, Joyce LS, Hon CS. Successful Treatment of Tattoo-Induced Pseudolymphoma with Sequential Ablative Fractional Resurfacing Followed by Q-Switched Nd: YAG 532 nm Laser. J Cutan Aesthet Surg. 2013 Oct. 6(4):226-8. [Medline]. [Full Text].

 
Previous
Next
 
This localized example of pseudolymphoma shows an ill-defined, thin, erythematous plaque.
Pseudolymphomatous drug eruption due to captopril, marked by erythematous to purple papules, patches, and plaques.
This erythrodermic pseudolymphoma (T-cell pattern) typifies drug-induced pseudolymphoma, which is most often secondary to anticonvulsant therapy.
Biopsy specimens of pseudolymphoma vary substantially, but they most often exhibit a mixed inflammatory infiltrate with prominent lymphoid follicle formation.
This example of lymphocytoma cutis shows a localized, erythematous-to-brown, ill-defined plaque.
Lymphocytoma cutis of the shoulder, composed of flesh-colored or erythematous nodules in small groups.
This photograph of lymphocytoma cutis caused by an arthropod bite shows an erythematous scaling patch of the scalp with localized secondary alopecia.
A mixed inflammatory infiltrate with germinal centers is indicative of lymphocytoma cutis.
Well-developed lymphoid follicles in a background of mixed inflammatory cells with small lymphocytes are typical of lymphocytoma cutis.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.